Trial reportDrug design, development and therapy2026
Fospropofol vs Propofol for Early Postoperative Nausea and Vomiting Prophylaxis in High-Risk Patients Undergoing Gynecological Laparoscopic Surgery: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative nausea and vomiting (PONV) is a common complication of gynecological laparoscopic surgeries. Although propofol has established antiemetic properties, the efficacy of its water-soluble prodrug, fospropofol, for PONV prophylaxis remains uncertain. The aim of this study was to compare the impact of fospropofol versus propofol on the incidence of PONV in high-risk patients undergoing gynecological laparoscopic surgery. Methods: In this prospective randomized controlled trial, 102 high-risk (Apfel score ≥3) female patients scheduled for elective gynecological laparoscopy were allocated to receive either fospropofol (FD group, n=51) or propofol (P group, n=51) for induction and maintenance, combined with sevoflurane inhalational anesthesia. The primary outcome was the incidence of PONV within the first 6 h postoperatively. Results: The incidence of PONV at 6 h was significantly lower in the FD group than in the P group (5.9% vs 19.6%; absolute risk reduction, 13.7%; Conclusion: A reduction in early PONV within 6 hours was observed with fospropofol compared to propofol, suggesting a potential role for fospropofol in early PONV prevention. Clinical Trial Registration: ChiCTR2500114542.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.